KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Net Cash Flow (2016 - 2025)

Sarepta Therapeutics has reported Net Cash Flow over the past 15 years, most recently at $188.2 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 79.21% year-over-year to $188.2 million; the TTM value through Dec 2025 reached -$304.2 million, down 145.09%, while the annual FY2025 figure was -$304.2 million, 145.09% down from the prior year.
  • Net Cash Flow for Q4 2025 was $188.2 million at Sarepta Therapeutics, up from $100.0 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $905.2 million in Q4 2024 and troughed at -$882.0 million in Q1 2022.
  • A 5-year average of -$34.9 million and a median of -$32.2 million in 2021 define the central range for Net Cash Flow.
  • Biggest five-year swings in Net Cash Flow: surged 1714.55% in 2021 and later tumbled 75526.58% in 2025.
  • Year by year, Net Cash Flow stood at $517.3 million in 2021, then crashed by 113.89% to -$71.8 million in 2022, then crashed by 62.95% to -$117.1 million in 2023, then surged by 873.16% to $905.2 million in 2024, then tumbled by 79.21% to $188.2 million in 2025.
  • Business Quant data shows Net Cash Flow for SRPT at $188.2 million in Q4 2025, $100.0 million in Q3 2025, and $269.7 million in Q2 2025.